2021
558TiP Phase I study of effector-function enhanced monoclonal antibody (mAb), SEA-TGT, in advanced malignancies
Ribrag V, Davar D, Garralda E, Curigliano G, Zain J, Mehta A, Minchom A, Sanborn R, Foss F, Oberoi H, Forero-Torres A, Ansell S. 558TiP Phase I study of effector-function enhanced monoclonal antibody (mAb), SEA-TGT, in advanced malignancies. Annals Of Oncology 2021, 32: s615-s616. DOI: 10.1016/j.annonc.2021.08.1080.Peer-Reviewed Original Research
2013
Treatment strategies for peripheral T-cell lymphomas
Foss FM. Treatment strategies for peripheral T-cell lymphomas. Best Practice & Research Clinical Haematology 2013, 26: 43-56. PMID: 23768640, DOI: 10.1016/j.beha.2013.04.005.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaAggressive first-line therapyAutologous stem cell transplantationConventional lymphoma therapyFirst-line therapyMajority of patientsStem cell transplantationSignal transduction inhibitorsHistone deacetylase inhibitorsFuture novel approachesLine therapyTransplant candidatesImproved survivalRelevant pathwaysAggressive diseaseCell transplantationInferior outcomesLymphoma therapyTransduction inhibitorsTreatment strategiesDeacetylase inhibitorsMonoclonal antibodiesMolecular profilingHeterogeneous group
2011
Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond
Foss F. Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond. Therapeutic Advances In Hematology 2011, 2: 161-173. PMID: 23556087, PMCID: PMC3573405, DOI: 10.1177/2040620711408491.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaT-cell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaFirst-line therapySubset of patientsAggressive clinical courseNon-Hodgkin lymphomaB-cell lymphomaHistone deacetylase inhibitorsCurative optionRefractory diseaseClinical courseCell transplantationTherapeutic advancesNew agentsTreatment approachesLymphomaDeacetylase inhibitorsMonoclonal antibodiesHeterogeneous groupProteasome inhibitorsNucleoside analoguesPatientsTherapyPeripheral T-cell lymphoma
Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood 2011, 117: 6756-6767. PMID: 21493798, DOI: 10.1182/blood-2010-05-231548.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaStandard chemotherapeutic regimensBest treatment strategyMore effective therapiesHistone deacetylase inhibitorsWorld Health OrganizationAbundance of drugsAggressive diseaseChemotherapeutic regimensPoor outcomeTreatment optionsClinical trialsEffective therapyTreatment strategiesTherapeutic approachesPrognostic issuesDeacetylase inhibitorsLymphoma classificationMonoclonal antibodiesGene expression profilingHeterogeneous groupHealth OrganizationProteasome inhibitorsDisease biology